FACULTY
Omid Hamid, MD
Chief of Research/Immuno-Oncology
The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
Los Angeles, CA
PROGRAM OVERVIEW
This online enduring program will provide healthcare providers with information needed to select first-line treatment for patients with unresectable or metastatic melanoma by incorporating evidence-based guidelines and applying current clinical trial data. This program will also review best practices for the management of adverse events associated with immunotherapy for unresectable or metastatic melanoma, as well as outline combination immunotherapy strategies for patients with advanced melanoma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician assistants who provide care for patients with advanced melanoma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Select first-line treatment for patients with unresectable or metastatic melanoma based on evidence-based guidelines and the most recent data from clinical trials of immunotherapy
- Discuss best practices for overall management of adverse events associated with single-agent or combination immunotherapy for unresectable or metastatic melanoma
- Review ongoing clinical trials of emerging combination immunotherapy strategies for melanoma
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.50 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Omid Hamid, MD | Consultant for Alkermes, Amgen, Bactonix, BeiGene, BioAtla, Bristol Myers Squibb, Eisai Biotech, Roche Genentech, Georgiamune, GigaGen, GritBIO, GlaxoSmithKline, ldera Pharmaceuticals, Immunocore, lncyte, lnstil Bio, IO Biotech, lovance Biotherapeutics, Janssen, KSQ Therapeutics, Merck, Moderna, NGM Bio, Novartis, Obsidian Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Tempus, Vial Health Technology, and Zelluna Immunotherapy; he is on Speakers Bureaus for Bristol Myers Squibb, Immunocore, Novartis, Pfizer, and Regeneron; he is part of institutional research sponsored by Arcus, Aduro, Akeso, Amgen, Bioatla, Bristol Myers Squibb, Cytomx, Exelixis, Roche Genentech, GlaxoSmithKline, lmmunocore, ldera, lncyte, lovance, Merck, Moderna, Merck Serano, Nextcure, Novartis, Pfizer, Regeneron, Seattle Genetics, Torque, and Zelluna Immunotherapy; and he also reports stock ownership in Bactonix |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, MSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Caitlin Rothermel, MPH, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: July 15, 2024
EXPIRATION DATE: July 15, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
